Sonikpreet Aulakh, MBBS, MD, discussed the shift toward multiomic personalization and tumor microenvironment reprogramming in neuro-oncology.
All News
The FDA has assigned a Prescription Drug User Fee Act date of November 27, 2026, for neladalkib in this ALK-positive non–small cell lung cancer population.
Advertisement
Explore key insights on operationalizing bispecific antibodies in community oncology, outpatient step-up dosing, and shared staffing infrastructure.
The FDA extends camizestrant review. Plus, promising Bria-IMT survival data and a ctDNA blood test that spots breast cancer recurrence 4 years early.
88 Imlunestrant With or Without Abemaciclib in Advanced Breast Cancer (ABC): A Subgroup Analysis in CDK4/6 Inhibitor (CDK4/6i)-Pretreated Patients From EMBER-3
ByCristina Saura,Lisa A. Carey, MD,Giuseppe Curigliano,Nadia Harbeck, MD, PhD,Joyce O’Shaughnessy, MD,François-Clément Bidard,Monica Lis Casalnuovo,Sung-Bae Kim,Eriko Tokunaga,Norikazu Masuda,Junichiro Watanabe,Xiaojia Wang,Quchang Ouyang,Hee Kyung Ahn,Christoph Cramer von Laue,Shanshan Cao,Holly Knoderer,Komal L. Jhaveri,Philippe Aftimos
Advertisement
Data from the phase 1/2 CADENZA trial support the approval of pivekimab sunirine for patients with blastic plasmacytoid dendritic cell neoplasms.
Orelabrutinib is now available in Australia for patients with relapsed/refractory mantle cell lymphoma.
The European Medicine Agency’s CHMP has adopted a positive opinion for encorafenib plus cetuximab and mFOLFOX6 in this treatment-naïve mCRC population.
Developers intend to submit a supplemental new drug application for toripalimab/chemotherapy in resectable stage II or III NSCLC.
Leading experts preview highly anticipated breast cancer data at ASCO 2026, including readouts from the SERENA-6, persevERA, and OPTIMA trials.
Researchers have shown that a single infusion of BCMA-directed CAR T cell therapy with cilta-cel produced rapid, sustained MRD-negative remissions in 20 patients with high-risk smoldering multiple myeloma.
Researchers have shown that mycophenolate mofetil accelerates neutrophil engraftment compared to methotrexate in cord blood transplantation.
Host Brandon Mancini, MD, MBA, FACRO, discusses stereotactic radiosurgery, proton therapy, and other relevant modalities in the management of brain tumors.
89 Imlunestrant With or Without Abemaciclib as First- and Second-Line Therapy in Advanced Breast Cancer (ABC): A Subgroup Analysis From the EMBER-3 Trial
ByPatrick Neven, MD, PhD,Andre Mattar,Antonio Llombart-Cussac,Giuseppe Curigliano,Nadia Harbeck, MD, PhD,Joyce O’Shaughnessy, MD,François-Clément Bidard,Monica Lis Casalnuovo,Sung-Bae Kim,Eriko Tokunaga,Cristina Saura,Lisa A. Carey, MD,Kamnesh R. Pradhan,Shanshan Cao,Monique Coersmeyer,Anna Emde,Francisco Sapunar,Komal L. Jhaveri,Philippe Aftimos
Nathan Goodyear, MD, outlined how exercise and nutrition can counter treatment-induced immunosenescence and improve long-term oncology outcomes.
Findings from a cohort study demonstrated that coexposure to a COVID-19 mRNA vaccine within 90 days of anti–PD-(L)1 treatment improved OS in patients with cancer.
Approval of the FoundationOne CDx may help identify patients with NSCLC harboring MET exon 14 skipping alterations who are candidates for tepotinib.
Identifying patients early is key for getting them into the CAR T-cell therapy pipeline, according to Saad Z. Usmani, MD, MBA, FACP, FASCO.
Mitchell E. Horwitz, MD, discussed how omidubicel and other advances in allogeneic transplantation have affected different hematologic oncology populations.
93 monarchE: Primary Overall Survival Results of Adjuvant Abemaciclib + Endocrine Therapy for HR+/HER2−, High-Risk, Early Breast Cancer
ByStephen R.D. Johnston,Miguel Martin, MD, PhD,Joyce O’Shaughnessy, MD,Roberto Hegg,Sara M. Tolaney, MD, MPH,Valentina Guarneri, MD,Lucia Del Mastro,Mario Campone,Javier Cortés, MD,Hope S. Rugo, MD,Matthew P. Goetz, MD,Erika P. Hamilton, MD,Elzbieta Senkus,Laura Testa,Patrick Neven, MD, PhD,Jens Huober, MD,Ran Wei,Maria Munoz,Priya Rastogi, MD,Nadia Harbeck, MD, PhD,Victoria Jennifer Stefaniak (Non-Author Presenter)
Nathan Goodyear, MD, discussed how structured exercise programs can reprogram the tumor immune microenvironment and enhance therapeutic efficacy.
95 monarchE: Subgroup Analysis of Adjuvant Abemaciclib + Endocrine Therapy for HR+/HER2−, High-Risk, Early Breast Cancer by Nodal Status
ByJavier Cortés, MD,Stephen R.D. Johnston,Miguel Martin, MD, PhD,Sara M. Tolaney, MD, MPH,Matthew P. Goetz, MD,Hope S. Rugo, MD,Joohyuk Sohn,Ozgur Ozyilkan,Miguel Henriques Abreu,Matthias Zaiss,Karina Maia Vianna,Hanne Melgaard Nielsen,Arlene Chan,Haralambos Kalofonos, MD,Serafin Morales,Belen San Antonio,Maria Munoz Fernandez,Sasha Amdur,Patrick Neven, MD, PhD,Brenda Grimes
96 Efficacy and Safety of Abemaciclib in Younger Patients With Early Breast Cancer in the monarchE Trial
ByNadia Harbeck, MD, PhD,Eleni Karapanagiotou,Fanny Le Du,Kevin Kalinsky, MD, MS,Shani Paluch-Shimon,Jasotha Sanmugarajah,Luis Costa,Einav Nili Gal-Yam,Joyce O’Shaughnessy, MD,Eriko Tokunaga,Sercan Aksoy,Rajnish Nagarkar,Brenda Grimes,Ran Jennifer Wei,Belen San Antonio,Katheryn Moreira,Hope S. Rugo, MD
Data from a phase 2 trial show that quizartinib plus omacetaxine mepesuccinate may better position patients to proceed to consolidative transplantation.
97 monarchE: Evaluation of Prognostic and Predictive Value of Ki-67 Index Pre- and Post-Neoadjuvant Chemotherapy and Changes Following NAC
ByJose Angel Garcia Saenz,Stephen R.D. Johnston,Nadia Harbeck, MD, PhD,Peter A. Fasching,Qiang Liu,Sema Sezgin Goksu,Ivan Toledano,Daphne T.F. Tsoi,Dorte Nielsen,Patricia Xavier Santi,Norikazu Masuda,Yoon Sim Yap,Margaret Block,Maria Munoz Fernandez,Brenda R Grimes,Jennifer Wei,Deli Liu,Miguel Martin, MD, PhD
Advertisement
Advertisement
Trending on CancerNetwork
1
Daraxonrasib/Vopimetostat Yield Stunning Response Rate in MTAP-del Pancreatic Cancer
2
Melanoma Trials You May Have Missed at ASCO 2026
3
80 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment (tx) for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer (a/mTNBC): Final Results From the Phase 1b/2 BEGONIA Study
4
Subcutaneous Isatuximab Earns EU Approval in Multiple Myeloma
5